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Introduction
It is well known that heart disease is the
leading cause of death in the United
States, with about 670,000 new diagnoses
of congestive heart failure (CHF) each year
(Suh et al., 2011). CHF results from a
number of different causes, produces
many different symptoms and occurs
when the heart muscle cannot efficiently
pump blood to the rest of the body (Suh et
al., 2011). In the United States, heart
failure (HF) and associated hospitalizations
are leading contributors to high health
care costs (Feltner et al., 2014). Up to one
fourth of patients hospitalized with HF are
readmitted within 30 days of discharge
(Feltner et al., 2014). In an effort to
reduce expenditures for the Centers for
Medicare & Medicaid Services (CMS), new
policies have been created to help reduce
readmission rates of HF patients (Feltner
et al., 2014). This has resulted in hospitals
providing special HF education prior to
discharge, HF coordinators, and HF clinics.
In our age of technology, there have been
many new innovations to help keep
patients with HF out of the hospital and
improve their quality of life. Some include
new medications, telemonitoring, and
implantable devices. The CardioMEMS HF
System is a new device, recently approved
by the U.S. Food and Drug Administration
(FDA), which will optimistically prevent
frequent hospitalizations for patients with
HF (U.S. Food and Drug Administration
[FDA], 2014). According to the FDA
(2014), the CardioMEMS HF System
monitors patient’s pulmonary artery
pressures (PAPs) and heart rate after a
small, battery-free device is permanently
implanted into the pulmonary artery. The
PA pressures and trends can be remotely
reviewed by the physician, who can then
adjust the patient’s medication regimen
(FDA, 2014). Thus far, the studies related
to the CardioMEMS HF System have been
very promising in keeping patients with HF
out of the hospital and improving his or
her quality of life.

Figure 1. Normal pressures in the
heart and pulmonary artery. Adapted
from Lancashire & South Cumbria
Cardiac Network, n.d.

Pathophysiology
When the heart, or myocardium, cannot
pump a sufficient amount of blood
throughout the body, for whatever reason,
it is simply termed congestive heart failure
(CHF) (Suh et al., 2011). However, CHF is a
complex condition that involves the
metabolic, neuroendocrine, and immune
systems (Wrigley, Lip, & Shantsila, 2011).
An abnormal heart muscle, or
cardiomyopathy, can be categorized as
primary or secondary, ischemic or nonischemic, and dilated, hypertrophic, or
restrictive (Frazier, Wung, Sparks,
Eastwood, 2009). All of which may lead to
CHF. There are two main categories of HF,
systolic and diastolic. Depending on when
in the cardiac cycle there is a deficiency,
depends on the type of HF. The heart can
have difficulties during systole, when the
heart muscle contracts and ejects blood
from the heart out to the lungs and body,
or during diastole, when the heart is at
rest and the chambers are filling with
blood (Suh et al., 2011). There are
additional classifications of left ventricular
failure, right ventricular failure, or
biventricular failure (Nicholson, 2014). It is
with left-sided heart failure when fluids
back up into the pulmonary system, thus
increasing the PAPs.
There are many pressures within the
heart, vessels, and lungs that can be
measured for diagnostic purposes. As
blood moves from the right ventricle into
the pulmonary artery, the pressure is
much lower than the blood pressure from
the left ventricle into the aorta. Normal
systolic pressures in the pulmonary artery
are less than 25 mm Hg and normal
diastolic pressures are less than 10 mm Hg
(Lancashire & South Cumbria Cardiac
Network). When PAPs rise, it could be
caused by a number of factors, but for
patients with HF, it is typically due to fluid
overload. Fluid and sodium intake need to
be decreased and diuretics may need to be
increased by the physician. For patients
with renal failure, they may need an extra
dialysis treatment.
While some pathological causes of CHF
may be reversible, such as infection and
thyroid imbalances, many causes are not,
such as hypertension and ischemic heart
disease (Nicholson, 2014). Coronary artery
disease (CAD), a very common cause of
CHF, results in coronary vessels becoming
blocked or occluded.

Heart tissue becomes ischemic and
progresses to infarction and necrosis of
the heart tissue resulting in HF. In
increased peripheral vascular resistance,
or hypertension, the heart has to work
harder to pump blood out of the heart.
Like any muscle, the harder the muscle has
to work, the larger it gets up to a certain
point. Frazier et al. (2009) describes
cardiac remodeling as either hypertrophy
or dilation. Heart cells, or myocytes,
change shape and increase in number to
compensate (Frazier et al., 2009).
Perfusion is maintained by the
compensatory changes of increased
vasopressin, activation of the reninangiotensin-aldosterone system, and
amplified adrenergic drive (Bergamini,
Cicoira, Rossi, & Vassanelli, 2009). These
changes cause the kidneys to reabsorb a
greater amount of water, thus increasing
blood volume to increase blood pressure
(Bergamini et al., 2009). However, the
increase in blood volume causes the heart
chambers to stretch. Along with chronic
pressure overload, these neurohumoral
stimuli are thought to contribute to the
development of cardiac hypertrophy
(Bergamini et al., 2009). However, over
time these compensatory mechanisms
result in negative effects seen in chronic
HF (Bergamini et al., 2009). Once the
myocardium stretches to the point where
it cannot contract strongly, the heart fails
to pump efficiently.
While there is still much research to be
done, there is evidence that monocytes,
inflammation, and oxidative stress play a
role in the pathophysiology of HF. Wrigley
et al. (2011) report that inflammatory
cytokines, such as tumor necrosis factor
(TNF), are released in HF and are
associated with LV dysfunction,
remodeling, and myocyte apoptosis.
When cardiac tissue is injured, monocytes
help rid the body of necrotic tissue by
phagocytosis and apoptosis (Wrigley et al.,
2011). As inflammation continues,
oxidative stress, which results when
aerobic cells produce an excessive amount
of reactive oxygen species (ROS), causes
cellular damage and cardiac fibrosis
(Bergamini et al., 2009). When the heart
tissue becomes fibrotic, or stiff, it cannot
pump as forcefully. Nitric oxide is also
produced which results in weakened
contraction of the myocardium (Wrigley et
al., 2011).

CardioMEMS HF System
When blood is not adequately
pumped out of the heart, the blood
volume backs up into other areas of
the body, such as the lungs or
periphery. When patients have
left-sided heart failure, blood backs
up into the pulmonary artery (PA)
and lungs. This results in
pulmonary edema, which causes
shortness of breath and even
respiratory failure. When the
pressures in the PA are directly
measured with the CardioMEMS HF
device, clinicians can remotely
monitor and proactively treat rising
PAPs before patients present with
symptoms related to
decompensating HF (St. Jude
Medical, Inc., 2014). In turn, this
keeps patients from being readmitted to the hospital for
exacerbations. Dr. Abraham (2014),
at Ohio State University, states that
the CardioMEMS heart failure
system is beneficial for patients
with systolic and/or diastolic heart
failure. The CHAMPION clinical
trials for the CardioMEMS HF
System showed a 28% reduction of
hospital re-admissions after six
months and a 37% reduction after a
year (St. Jude Medical, Inc., 2014).

Figure 2. Antenna and wireless electronics unit.
Adapted from St. Jude Medical, Inc., 2014

The CardioMEMS HF system consists
of a small, battery free sensor, an
antenna, and a wireless electronics
unit. The sensor is permanently placed
by a physician under fluoroscope into
the PA via the femoral vein (St. Jude
Medical, Inc., 2014). The sensor cannot
be felt and will not interfere with other
implanted devices, such as a
pacemaker; however, as with any
invasive procedure, there are rare
complications that can occur (St. Jude
Medical, Inc., 2014). Of note, 98.8% of
patients in the clinical trial were free
from complications related to the
device (St. Jude Medical, Inc., 2014).
Each morning the patient will take a
few minutes to lay on a pillow
containing the paddle-shaped antenna.
The electronics unit will then read the
patients PAPs and send them to a
secure website that his or her doctor
can access (St. Jude Medical, Inc.,
2014). By directly measuring the
pressures in the PA, physicians can
adjust patients’ medications before
they develop symptoms of worsening
heart failure due fluid retention (Rose
& Abraham, 2014). This not only helps
keep patients at home and out of the
hospital, but it improves their quality of
life (Rose & Abraham, 2014).

Figure 3. Adapted from St. Jude Medical, Inc.,
2014

Nursing Implications
It is inevitable that nurses will care for patients with some degree of CHF. It is
important for nurses to understand the pathophysiology of HF. In doing so, nurses
can better educate and treat patients. In the hospital setting, nurses can screen
patients for risks of re-admission and advocate for patients so they can receive
available services at home (Smith, 2013). Frazier et al. (2009) stress that clinicians
should update their education on genetics and genetic testing as genetic discoveries
related to HF are made. Nurses play a pivotal role in the education of HF including
medications, devices, diet and lifestyle changes. The more patients understand
their illness, the more likely they are to better manage their disease (Falk, Ekman,
Anderson, Fu, & Granger, 2013). In the case of the CardioMEMs HF System, the
nurse should educate the patient on post-procedure care. Because the clinician will
be adjusting the patient’s medications regularly, it is important that the patient fully
understands the medication(s). It is also important that nurses provide emotional
support and help patients with HF cope with the loss of independence, social
isolation, and fear of the impending progression of his or her HF (Falk et al., 2013).

Signs & Symptoms
Depending on the type of myocardial
dysfunction and the progression of the
disease results in different signs and
symptoms related to HF. The New York
Heart Association (NYHA) uses a four class
system to classify symptoms and monitor
progress (Nicholson, 2014). The
CHAMPION clinical trial studied patients
with class III heart failure (St. Jude Medical,
Inc., 2014). Patients with class III HF have
obvious limitations and excessive
breathlessness, fatigue or palpitations
(Nicholson, 2014). Other clinical
presentations of HF include orthopnea,
nocturnal cough and dyspnea, peripheral
edema, bloating, loss of appetite,
confusion, angina, and syncope (Nicholson,
2014). Nicholas (2014) also lists signs that
someone may have HF and might include
tachypnea, tachycardia, irregular pulse,
wheezing, weight changes, jugular venous
distention (JVD), abnormal heart sounds
such as a gallop or murmur, and pleural
effusions. These effects of HF are what
limit patient’s activities of daily living and
have been found to contribute to
depression and a decreased quality of life.

Conclusion
As the baby boomers continue to age,
there will undoubtedly be an increase in
the number of people living with CHF.
While focus should remain on preventative
care, education, and decreasing risk factors
for developing HF, the goals of care will
continue to be improving quality of life
while providing cost-effective and
evidence-based care (Smith, 2013).
Patients with HF require frequent office
and/or clinic visits for medication titration
and symptom monitoring; however,
disability, transportation, and cost could be
barriers for compliance of these visits
(Smith, 2013). Patients with the
implantable CardioMEMs HF System can be
monitored from the comfort of their home
and optimistically decrease hospitalizations
related to HF symptoms. As further
research continues with medications,
devices, and at the cellular level, the
CardioMEMs HF System can safely improve
the quality of life for patients with HF.
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